KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $430,689 | +11.2% | 24,795 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $387,468 | +21.1% | 27,519 | -7.5% | 0.00% | 0.0% |
| Q1 2023 | $320,056 | -29.2% | 29,745 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $451,947 | +31.0% | 30,170 | +12.4% | 0.00% | 0.0% |
| Q3 2022 | $345,000 | +25.0% | 26,851 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $276,000 | +31.4% | 28,503 | +35.1% | 0.00% | – |
| Q1 2022 | $210,000 | -77.2% | 21,100 | -57.5% | 0.00% | -100.0% |
| Q1 2021 | $920,000 | -3.8% | 49,700 | -8.1% | 0.00% | 0.0% |
| Q4 2020 | $956,000 | +19.9% | 54,100 | +4.0% | 0.00% | 0.0% |
| Q3 2020 | $797,000 | +36.7% | 52,000 | +127.1% | 0.00% | 0.0% |
| Q2 2020 | $583,000 | +75.1% | 22,900 | +6.5% | 0.00% | +100.0% |
| Q1 2020 | $333,000 | +42.3% | 21,500 | +24.3% | 0.00% | 0.0% |
| Q2 2019 | $234,000 | – | 17,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |